Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23885771 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL29183209 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL22612643 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL21748791 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL3124376 | 1.00 | ALDH1A1 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL28502789 | 0.98 | GNAI3 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| Hydrochloric Acid SCHEMBL28502790 | 0.98 | GNAI3 (0.33) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL22496874 | 0.84 | LMNA (0.37) | ALDH1A1ACHENPC1LMNAMEN1 | |
| SCHEMBL2377686 | 0.84 | EPHX2 (0.37) | ALDH1A1NPC1CHRNA7 | |
| SCHEMBL16169058 | 0.84 | EPHX2 (0.37) | ALDH1A1NPC1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-8071605-B2 | Piperidine compounds for use in the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| WO-2010067123-A1 | 2- (PIPERIDIN-1-YL) -4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | NISCH, PAK6, MYD88 | ALDH1A1 609/4885ACHE 545/4885NPC1 762/4885 |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | ALDH1A1 3701/4885ACHE 2246/4885NPC1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.